Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (421-430 of 692) with videos related to

Pageof 70
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
Benefit of a second opinion for lung cancer: no recurrent disease, but infectionRomane M Schook, Schook M Romane, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancerRoderick H J Breuer, Peter J F Snijders, Thomas G Sutedja, et al.
Anticancer Research|September 3, 1999
99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumoursM Bakker, W T van der Graaf, D A Piers, et al.
Clinical Lung Cancer|March 29, 2017
Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the NetherlandsNaomi van der Linden, Mathilda L Bongers, Veerle M H Coupé, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical TrialsBarend J Sikkema, Sara J Baart, Marthe S Paats, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2015
Costs of non-small cell lung cancer in the NetherlandsN van der Linden, M L Bongers, V M H Coupé, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 1, 1994
Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assayS Withoff, E F Smit, G J Meersma, et al.
ESMO Open|August 13, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesC A Powell, S Modi, H Iwata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Pageof 70

Showing results (421-430 of 692) with videos related to

Sort By:
Pageof 70
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
Benefit of a second opinion for lung cancer: no recurrent disease, but infectionRomane M Schook, Schook M Romane, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancerRoderick H J Breuer, Peter J F Snijders, Thomas G Sutedja, et al.
Anticancer Research|September 3, 1999
99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumoursM Bakker, W T van der Graaf, D A Piers, et al.
Clinical Lung Cancer|March 29, 2017
Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the NetherlandsNaomi van der Linden, Mathilda L Bongers, Veerle M H Coupé, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical TrialsBarend J Sikkema, Sara J Baart, Marthe S Paats, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2015
Costs of non-small cell lung cancer in the NetherlandsN van der Linden, M L Bongers, V M H Coupé, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 1, 1994
Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assayS Withoff, E F Smit, G J Meersma, et al.
ESMO Open|August 13, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesC A Powell, S Modi, H Iwata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Pageof 70